1 / 24

OMS ElectroOncology Precision Tumor Destruction and DNA Based Cancer Immunotherapy

OMS ElectroOncology Precision Tumor Destruction and DNA Based Cancer Immunotherapy. OTCBB: ONCS Punit Dhillon President & CEO. Forward Looking Statement.

lisbet
Download Presentation

OMS ElectroOncology Precision Tumor Destruction and DNA Based Cancer Immunotherapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. OMS ElectroOncology Precision Tumor Destruction and DNA Based Cancer Immunotherapy OTCBB: ONCS PunitDhillon President & CEO CONFIDENTIAL

  2. Forward Looking Statement Our commentary and responses to your questions may contain forward-looking statements, including comments concerning clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of OncoSec’s technology by potential corporate partners, capital market conditions, timing of events, cash consumption and other subjects. Information concerning factors that could cause actual results to differ materially from those set forth in our regulatory filings from time to time. CONFIDENTIAL

  3. Investment Overview • CancerTherapy with OMS ElectroChemotherapy and OMS ElectroImmunotherapy • Ablation platform selectively destroys cancer cells while leaving healthy tissue intact, dramatically improving patient quality of life • Immunotherapyplatform allows activation of both innate and adaptiveimmunity to kill cancer cells • Drug-device combination using low dose bleomycin or DNA based cytokines • Locally delivered with electroporation into targeted tumors/tissue • Selective killing of cancer cells, preserving healthy tissue • Extensive human clinical experience showing efficacy and strong safety profile in Phase 1 - 4 clinical trials of 400+ patients: cutaneous (BCC, SCC, melanoma), head & neck, breast, prostate, pancreatic tumors • Near-term commercial potential, recurring sales model CONFIDENTIAL

  4. OncoSec Solution = OMS ElectroOncology OncoSec’s treatment platform has two components: Anti-Cancer Agent OncoSec Medical System (OMS) Cytokine Plasmid DNA Construct (e.g. IL-12) Chemotherapeutic Agent (Bleomycin) or • Patent estate • Electric pulse generators and applicators • Electroporation conditions and methods of use • Drug-device combination • Razor-razor blade marketing strategy with revenue from single use disposable; potential profit from proprietary biologics CONFIDENTIAL

  5. Electroporation Enhances Therapeutic Potency Electroporation: millisecond pulses increase cell permeability Drug surrounds cells Cell poration; agent enters cells Cells reseal, allowing agent to perform its function Tissue electroporation enhances cellular uptake Anti-cancer agent injected directly into tissue Electroporation dramatically enhances cellular uptake of a useful therapeutic agent CONFIDENTIAL

  6. OMS ElectrOncology Cancer Targets OncoSec’s ElectroOncology has successfully treated a range of solid tumor cancers in humans • Skin (Melanoma and Non-Melanoma) • Head & Neck • Breast • Prostate • Pancreatic CONFIDENTIAL

  7. OMS ElectoImmunotherapy • DNA plasmids encoding for cytokines (e.g. IL-12) to stimulate the body’s immune system to kill cancer cells • DNA plasmid encoding for cytokines in combination with OMS  increased cellular uptake of DNA immunotherapeutic  subsequent production/expression of IL-12 • Induces innate and adaptive anti-tumor immune responses • Nounwantedimmuneresponses and immunogenic effects associated with protein IL-12 administered directly into the body • No unwanted immune responses and immunogenic effects often attributed to viral vectors • Lead drug candidate is a DNA plasmid construct coding for interleukin-12 (IL-12) • Phase II clinical pipeline for several cancer indications based on positive Phase I clinical data Boosting the immune system to fight cancer CONFIDENTIAL

  8. TH1 OncoSec’s Lead Candidate: IL-12 How it works • DNA IL-12 uptake into tumor cells enhanced by electroporation • Cells produce and secreteIL-12 • IL-12 recruits macrophages and cytotoxic T-cells and activates other pro-inflammatory responses – innate immune respone • Cancer cells and tumors at local treatment site destroyed • Selective systemic adaptive immune effect on remote, untreated cancer lesions B-cell IL-12 recruits cytotoxic T-cells and macrophages TH1 Apoptosis IFN- IL-12 Macrophage Inhibits tumor angiogenesis IFN- Phagocytosis Antibodies Safe and effective local and systemic immune response and therapeutic benefit CONFIDENTIAL

  9. IL-12 Plasmid in Melanoma Mouse Model - I Lucas et al., 2002, IL-12 plasmid delivery by in Vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma, Molecular Therapy Intratumoral delivery of IL-12 by electroporation demonstrated: • Cytokine expression within the tumor • Potential anti-angiogenic effect (prevents growth of blood vessels that feed tumor) • Tumor control in all treated animals • Long-term survival and resistance to challenge in melanoma model CONFIDENTIAL

  10. IL-12 Plasmid in Melanoma Mouse Model - II Tumor response at day 30 post-treatment N = 50 animals; 10 animals per group; 5 females, 5 males per group. Heller et al., 2006, Evaluation of toxicity following electrically mediated IL-12 gene delivery in a B16 mouse melanoma model, Clin Can Res • Electroporation increased desired immune response and potency of DNA IL-12 • Higher dose achieved significantly higher partial tumor response rates including complete responses in one study cohort • Study also showed no significant toxicity associated with DNA IL-12 CONFIDENTIAL

  11. US Phase I Melanoma Trial Results B B A C B E F D • Dose escalation clinical study in patients with metastatic melanoma • Treatment with OMS and IL-12 completed in 24 patients at University of Southern Florida, Moffitt Cancer Center • US Phase I results reported in Journal of Clinical Oncology (Daud et al, 2008): • Study established efficacy, safety and tolerability • Evidence of systemic response (objective response) in 53% of patients with distal (remote) metastases that were untreated • 15% of patients demonstrated 100% clearance of distal, non-treated tumors; only 0.25% could be expected to spontaneously regress based on historic clinical data • Greater then 90% of locally treated lesions showed evidence of necrosis (histological biopsy) Pre-Treatment Day 256 Day 637 Best in class Phase I study results support initiation of Phase II study Right Front Chest Wall Right Upper Back CONFIDENTIAL

  12. Phase II Study Design for OMS-I100 (Melanoma) CONFIDENTIAL

  13. Phase II Study Design for OMS-I110 (MCC) CONFIDENTIAL

  14. Phase II Study Design for OMS-I120 (CTCL) CONFIDENTIAL

  15. OMS ElectroChemotherapy • Chemotherapeutic agent (bleomycin) delivered intracellularly with electroporation • Chemical based ablation, unlike surgery, radio frequency ablation and cryotherapy that has the ability to selectively kill cancer • Clinical and physician experience in late stage head & neck and skin cancer studies demonstrated therapy to be a safe, tissue sparing, easy to use, economical and highly effective alternative to surgery • OncoSec’s new clinical developmentplan is to maximize the likelihood of clinical and regulatory success Precision tumor ablation enhancing patient quality of life CONFIDENTIAL

  16. Treatment of Head andNeck Cancer Electroporation applied with applicator Tumor injectedwith bleomycin Cancer cells destroyed while preserving healthy tissue No removal of healthy tissue CONFIDENTIAL

  17. Treatment of Skin Cancer OMS ElectroChemotherapy of basal cell cancer BCC of Earlobe Tumor cells turn black as they die 30 Days Post-treatment Pre-Treatment Natural wound healing No further evidence of tumor 90 Days Post-Treatment 120 Days Post-Treatment Surgery would have required cutting out portion of ear CONFIDENTIAL

  18. CutaneousCancer Therapy Clinical Data (H.Lee Moffitt Cancer Center – University of Florida) • Complete response (CR) + partial response (PR)Heller et al., Cancer Vol. 83 (1), July 1, 1998 Complete response is similar to treatment by surgery, without removal of healthy tissue CONFIDENTIAL

  19. OncoSec Product Pipeline Completed Planned CONFIDENTIAL

  20. OncoSec Competitive Advantages Compelling stakeholder benefits and promise of market pull • Improved cosmetic, functional and pain outcomes →patient preference • Minimal tissue removal = simple post-op care → physician & payer preference • Transcends tumor types & locations →physician preference • Adjuvant therapy = easier adoption →physician preference • Ease of use and higher income →physician preference • Minimal upfront investment→institutional acceptance • Fast procedure = operating room cost savings → payer preference Benefits all aspects of healthcare including the Patient CONFIDENTIAL

  21. Board & Executive Management Team Board of Directors Executive Management AvtarDhillon, M.D., ChairmanInovio Pharmaceuticals, MDS Capital (Lumira) James DeMesa, M.D., Director Stem Cell Therapeutics, Induce Biologics Anthony E. Maida III, Ph.D., Director BioConsul Drug Development, Replicon Neurotherapeutics, Trellis Bioscience, CancerVax Corp. PunitDhillon, President & CEOInovio Pharmaceuticals, MDS Capital (Lumira) PunitDhillon, President & CEOInovio Pharmaceuticals, MDS Capital (Lumira) Michael Cross, Ph.D., Chief Business Officer MDS Capital, GrowthWorks, MDS Proteomics, Viventia Biotech Veronica Vallejo, CPA, Vice President Finance CBIZ MHM, Mayer Hoffman & McCann Caryn Peterson, Ph.D., Vice President Regulatory Affairs FeRx, Amylin Pharmaceuticals, Hybertech Paul Goldfarb, M.D., Medical Director Scripps Health, University of California, San Diego Brian McCluskey, B.Eng., Executive Director Engineering TDI Instruments, Digirad Corp. Ernest Kitt, Executive Director Clinical Operations Medicinova, Vical Corp. CONFIDENTIAL

  22. Financial Information CONFIDENTIAL

  23. Commercialization Milestones • Based on leveraging large historical patient database • Initiate multiple OMS ElectroImmunotherapy trials for skin cancers • Initiate US pivotal OMS ElectroChemotherapy trials for skin cancer • Extend EU pre-marketing studies demonstrating pharmacoeconomic, reimbursement, and QoL benefits • Develop OMS ElectroImmunotherapy combination Phase II program for skin cancers • Near-term commercialization strategy: initiate pivotal and pre-marketing clinical trials, secure early market adoption, expand physician use base: • Obtain marketing approvals and reimbursement coding • Sales and marketing through partnerships • Drive adoptionvia key opinion leaders, physician loyalty and advocacy groups • Partner/co-develop in emerging countries: large and rapidly growing markets with both push and pull dynamics (device improvements) CONFIDENTIAL

  24. Business Opportunity Summary • $1B market for locally effective, tissue sparing tumor treatment • Cancer therapy using biologics and small molecules: diversified • Market exclusivity through potential orphan indications • Market ready with favorable pharmacoeconomics & quality of life benefits • Centers of Excellence/key opinion leaders to drive adoption • Management team with extensive drug, device, clinical, commercial and • capital markets expertise CONFIDENTIAL

More Related